GlassScriptPhysician profile
Scott L Thiel
NPI 1750359816
$1,151.91
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $85.51 · 2021: $119 · 2022: $298 · 2023: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $215.45 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.69 | 2019-2023 | Jardiance |
| Amgen INC. | $112.51 | 2019-2022 | |
| Abbvie INC. | $70.36 | 2022-2023 | Qulipta |
| Smith+Nephew, INC. | $66.71 | 2019-2021 | |
| Abbott Laboratories | $65.86 | 2021-2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $50.46 | 2020-2023 | Mounjaro |
| Pfizer INC. | $45.09 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $38.20 | 2019-2023 | |
| Exact Sciences Corporation | $37.38 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $33.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.53 | 2020-2023 | Trulance, Xifaxan |
| Dexcom, INC. | $26.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.28 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $24.71 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.21 | 2023 | Gvoke Hypopen |
| Organogenesis INC. | $15.43 | 2019 | |
| Kci USA, INC. | $15.17 | 2023 | Kerramax Care, V.A.C. Dermatac, Activ.A.C. |
| Glaxosmithkline, LLC. | $14.98 | 2022 | |
| Genentech USA, INC. | $14.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.66 | 2023 | |
| Horizon Therapeutics Plc | $12.78 | 2022 | |
| Allergan, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Thiel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.